A cost analysis of febrile neutropenia management in Australia: Ambulatory v. in-hospital treatment

Australian Health Review

Volumn 35, Issue 4, 2011, Pages 491-500

  Lingaratnam, Senthil ^a   Worth, Leon J ^a   Slavin, Monica A ^a,b   Bennett, Craig A ^a   Kirsa, Suzanne W ^a   Seymour, John F ^a   Dalton, Andrew ^c,d   Koczwara, Bogda ^e,f   Prince, H Miles ^a,g,h   O'Reilly, Mary ^g,i,j   Mileshkin, Linda ^a   Szer, Jeff ^b,k   Thursky, Karin A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ADhealth Pty Ltd   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

^g CABRINI INSTITUTE   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ Victoria Parade ^*  (Australia)

^j MONASH UNIVERSITY   (Australia)

^k Western and Central Melbourne Integrated Cancer Services   (Australia)

more..

Author keywords

ambulatory care; costs; economics

Indexed keywords

EID: 82155188494     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH10951     Document Type: Article

References (31)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34(6): 730-51. doi:10.1086/ 339215 (Pubitemid 34194843)
2. Lingaratnam S, Slavin MA, Koczwara B, Seymour JF, Szer J, Underhill C, et al. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee. InternMedJ 2011; 41: 75-81. doi:10.1111/j.1445-5994.2010.02338.x
3. Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009; 101(Suppl. 1): S18-22. doi:10.1038/sj.bjc.660 5272
4. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: Time to revise the present treatment strategy. J Support Oncol 2008; 6(5): 199-208. (Pubitemid 351836606)
5. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24(25): 4129-34. doi:10.1200/JCO.2005.03.9909 (Pubitemid 46622289)
6. Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004; (4): CD003992.
7. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18(16): 3038-51. (Pubitemid 30644129)
8. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12(1): 107-14. (Pubitemid 24020628)
9. Worth LJ, Lingaratnam S, Taylor A, Hayward AM, Morrissey S, Cooney J, et al. Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41(1b): 82-9. doi:10.1111/j.1445-5994. 2010.02339.x
10. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26(4): 606-11. doi:10.1200/ JCO.2007.13.8222 (Pubitemid 351264355)
11. HidalgoM,Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial. Cancer 1999; 85(1): 213-9. doi:10.1002/(SICI)1097-0142(19990101)85:13.3.CO;2-4 (Pubitemid 29031377)
12. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study. Br J Cancer 2003; 89(1): 43-9. doi:10.1038/sj.bjc.6600993 (Pubitemid 36897933)
13. Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004; 54(1): 29-37. doi:10.1093/jac/dkh303 (Pubitemid 39028964)
14. Lingaratnam S, Slavin MA, Mileshkin L, Solomon B, Burbury K, Seymour JF, et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J 2011; 41: 110-20. doi:10.1111/j.1445-5994.2010.02342.x
15. de Lalla F. Outpatient therapy for febrile neutropenia: Clinical and economic implications. Pharmacoeconomics 2003; 21(6): 397-413. doi:10.2165/00019053-200321060-00004 (Pubitemid 36461403)
16. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 2004; 12(9): 657-62. (Pubitemid 39280317)
17. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of theImmunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002; 35(12): 1463-8. doi:10.1086/344650 (Pubitemid 36020688)
18. Lingaratnam S, Thursky KA, Slavin MA, Kirsa SW, Bennett CA, Worth LJ. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: Analysis of the Victorian Admitted Episodes Dataset. Intern Med J 2011; 41(1b): 121-9. doi:10.1111/j.1445-5994. 2010.02343.x
19. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: Adventures in the science and art of treatment choices. Support Care Cancer 2002; 10(3): 189-96. doi:10.1007/s005200100300 (Pubitemid 36056293)
20. Leese B. The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 1993; 29(Suppl. 7): S15-8. doi:10.1016/0959-8049(93) 90611-.I. (Pubitemid 24037724)
21. KernWV,Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341(5): 312-8. doi:10.1056/NEJM199907293410502 (Pubitemid 29350301)
22. National Hospital Cost Data Collection Round 12 (2007-2008). Cost Report. Australian Government of Health and Ageing; 2009.
23. Health Purchasing Victoria Contract 2010-2014. Health Purchasing Victoria; 2010.
24. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992; 339(8801): 1092-6. doi:10.1016/0140-6736(92) 90674-.R.
25. Giamarellou H, Bassaris HP, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 2000; 44(12): 3264-71. doi:10.1128/AAC.44.12.3264-3271.2000 (Pubitemid 33009482)
26. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: Feasibility and safety in routine clinical practice. Support Care Cancer 2008; 16(5): 485-91. doi:10.1007/s00520-007-0334-8 (Pubitemid 351502757)
27. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10(2): 316-22.
28. Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 1997; 15(3): 237-42. doi:10.3109/07357909709039721 (Pubitemid 27261664)
29. Calhoun EBS, Kozloff M, Bennett C. Uncompensated costs associated with the outpatient management of cancer chemotherapy-associated febrile neutropenia. Community Oncol 2005; 2(4): 293-6. (Pubitemid 41104683)
30. Health expenditure Australia 2007-2008. Australian Institute of Health and Welfare; 2009. Health and Welfare Expenditure Series, Number 37.
31. Ásgeirsdóttir B (Deputy Secretary-General OECD). Speech to the IX Forum International de la gestion de la santé organisé par les Echos [Speech to the IX Forum International de la gestion de la santé organisé par les Echos]. 2004. Available at http://www.oecd.org/ dataoecd/57/17/ 23435997.pdf [verified 13 October 2011].